Why ECPC Matters
The challenge of access to medicines is of crucial importance to millions of Europeans affected by cancer every year. Whilst no one country is immune to access issues, some regions and countries in Europe face greater difficulties than others. Several factors have an impact on access to medicines, from regulatory standards to funding systems and the varying nature of healthcare systems across Europe – all adding to inequalities across Europe. The European Parliament adopted a report, on its own initiative, on the ‘Options for Improving Access to Medicines’ – presenting an opportunity for the European Parliament to take a proactive stance on the issue of access to medicines. It makes several calls for action aimed at EU and Member State institutions to address the most urgent challenges when it comes to access to medicines, stressing the added value of European cooperation.
Report: Unlocking the potential of precision medicine in Europe
Biomarker tests are essential tools in the diagnosis and treatment of cancer. How can they help transform cancer care?
Read and share the full report.
New HTA toolkit
The European Cancer Patient Coalition has launched an online education (e-learning) module for patient organisations and patient advocates. Their unique knowledge, perspectives and experiences are crucial in determining the value of new treatments in the Health Technology Assessment (HTA).
People living with cancer and their carers best understand the need for new therapies and their impact on quality of life.
The module aims to equip our members and broader patient community with knowledge for participating in the HTA of cancer treatments.
Personalised Medicine Booklet
The European Cancer Patient Coalition launched “Personalised Medicine: A Guide for Patients” – a booklet to address the opportunities and challenges that personalised medicine provides, so that the needs of cancer patients across Europe are met.